Experts Warn Channel Islands on Cannabis Prescribing Risks

Warning Comes as Islands Weigh Program Expansion

Medical professionals testified before Channel Islands health authorities, urging caution as the jurisdiction considers broadening its nascent medicinal cannabis framework. The testimony follows a 2025 pilot program that allowed limited prescribing for chronic pain and epilepsy. Policymakers are now weighing whether to expand qualifying conditions and allow higher-potency formulations.

US State Programs Cited as Cautionary Tale

Experts pointed to regulatory gaps in California, Oklahoma, and Michigan as examples of what to avoid. Loose oversight in those states allowed dispensaries to operate without solid product testing, patient registry enforcement, or limits on THC concentration. California's Bureau of Cannabis Control reported in 2024 that 40% of sampled products exceeded labeled potency by more than 15%.

Witnesses urged the Channel Islands to mandate third-party lab testing, cap THC at 20% for flower and 70% for concentrates, and require prescriber training before issuing cannabis recommendations.

Mental Health Risks Highlighted in Young Adults

Psychiatrists flagged studies linking high-potency cannabis use to first-episode psychosis in individuals aged 16-25. A 2025 meta-analysis published in The Lancet Psychiatry found that daily use of cannabis with THC content above 10% doubled the risk of psychotic disorders compared to non-users. The risk tripled in those with a family history of schizophrenia.

One expert noted that the Channel Islands' small population makes it easier to track adverse events. That same small population means a handful of cases could strain mental health services.

Cannabis Use Disorder Prevalence in Medical Programs

Data from Colorado's medical cannabis registry show that 18% of patients met DSM-5 criteria for cannabis use disorder within two years of enrollment. That figure rose to 27% among patients who began using before age 21. The disorder is characterized by tolerance, withdrawal, unsuccessful attempts to cut down, and continued use despite negative consequences.

Experts recommended that Channel Islands clinicians screen for substance use history and offer harm-reduction counseling at every follow-up visit.

Prescriber Training and Oversight Gaps

Witnesses criticized the lack of mandatory continuing education for cannabis-prescribing physicians in most US states. In states without training requirements, some doctors issued hundreds of recommendations per month with minimal patient evaluation. One Michigan physician authorized 4,200 patients in 2023 before the state suspended his license.

The Channel Islands medical board has proposed requiring 8 hours of accredited training in endocannabinoid pharmacology, drug interactions, and mental health screening before a clinician can prescribe cannabis.

Product Testing and Labeling Standards Urged

Experts called for mandatory testing of all medicinal cannabis products for potency, pesticides, heavy metals, and microbial contaminants. They recommended adopting ISO 17025-accredited lab protocols and requiring batch-specific certificates of analysis on every package. Labels should display THC and CBD content in milligrams per dose, not just percentages.

The Channel Islands currently lack a licensed testing laboratory. Products are imported from UK suppliers under a temporary framework.

What Happens Next

The Channel Islands health committee will vote on proposed regulations in June 2026. The draft framework includes a 15% THC cap for flower, mandatory lab testing, and a patient registry linked to the national prescription database. Public comment closes May 30. For full background on the program's development, see the CannIntel topic hub on Channel Islands Medical Cannabis.

If adopted, the rules take effect in Q4 2026. Licensed dispensaries would open in early 2027. We'll be watching whether the committee adopts the stricter THC caps experts recommended or opts for the higher 20% threshold in the current draft.